At first, the benefit of reducing the number of HF hospitalisations in SGLT2 inhibitor trials [1–6] primarily reflected prevention of symptomatic HF in DM2 patients at high risk, as approximately 90% did not have HF at baseline (and those who did, were not well characterised). This evidence concerns the gene SLC5A2 and hydrops fetalis.